Hepatitis C News and Research

Latest Hepatitis C News and Research

Scientists provide insight into emergence of inter-species transmittable viruses

Outbreaks such as the severe acute respiratory syndrome (SARS) Middle East respiratory syndrome coronavirus (MERS) have afflicted people around the world, yet many people think these trends are on the decline.

13 Aug 2013

FDA: New drug Tivicay approved to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.

13 Aug 2013

Expansion of heroin, opioid medical treatment needed to reduce overdose deaths

A new report from Simon Fraser University researcher Bohdan Nosyk calls for the expansion of heroin and opioid medical treatment to stem the increase of overdose deaths.

7 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

New findings may lead to first new animal model for hepatitis C virus

By differentiating monkey stem cells into liver cells and inducing successful infection, researchers from the Icahn School of Medicine at Mount Sinai have shown for the first time that the hepatitis C virus can replicate in monkeys, according to research published in the journal Gastroenterology.

3 Aug 2013

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.

31 Jul 2013

Study: About 50% of fibromyalgia patients have nerve damage

About half of a small group of patients with fibromyalgia - a common syndrome that causes chronic pain and other symptoms - was found to have damage to nerve fibers in their skin and other evidence of a disease called small-fiber polyneuropathy (SFPN). Unlike fibromyalgia, which has had no known causes and few effective treatments, SFPN has a clear pathology and is known to be caused by specific medical conditions, some of which can be treated and sometimes cured.

31 Jul 2013

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Genotype 1 is, worldwide, the most prevalent genotype of the hepatitis C virus. It accounts for around seventy percent of all hepatitis C infections.

30 Jul 2013

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Call it therapeutic poop, if you will, but the best hope yet for an effective treatment of childhood infections with the drug-resistant bacterium C. difficile may come straight from the gut, according to recent research.

30 Jul 2013

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

The USPSTF agreed with the CDC that since most patients (75%) who are currently infected with hepatitis C were born between 1945 - 1965, and since risk-based screening has not been successful in identifying these individuals, that a one time age-based hepatitis C blood test was necessary.

29 Jul 2013

World Hepatitis Alliance calls for urgent action to address viral hepatitis

On World Hepatitis Day, the World Hepatitis Alliance has called for urgent attention to be given to recent figures showing that although viral hepatitis kills as many as HIV/AIDS, the great majority of countries have no programmes in place to tackle it.

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

A Miriam Hospital researcher has joined forces with international colleagues to call for new strategies to better manage and improve assessment and treatment for hepatitis C (HCV) infection in individuals who inject drugs.

26 Jul 2013

Combination treatment can reduce hepatitis C infection in people who inject drugs

The burden of liver disease could be dramatically reduced by scaling up the combination of interventions for hepatitis C infection among people who inject drugs according to University of Bristol researchers. The findings, published today [24 July], form part of new global recommendations on treating the virus.

25 Jul 2013

Combination of 6 comprehensive measures to prevent spread of hepatitis C

UC San Francisco researchers are recommending a combination of six comprehensive measures to prevent the spread of hepatitis C, in an effort to address the more than 31,000 young people they estimate may be newly infected with the virus each year in the United States due to injection-drug use.

25 Jul 2013

WHO urges governments to act against five hepatitis viruses that cause severe liver infections

On World Hepatitis Day (28 July), the World Health Organization (WHO) is urging governments to act against the five hepatitis viruses that can cause severe liver infections and lead to 1.4 million deaths every year. Some of these hepatitis viruses, most notably types B and C, can also lead to chronic and debilitating illnesses such as liver cancer and cirrhosis, in addition to loss of income and high medical expenses for hundreds of millions of people worldwide.

24 Jul 2013

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.

24 Jul 2013

Researchers provide new model for studying drug targets and therapies for AIH

A gene mutation disrupts the activity of certain immune cells and causes the immune system to erroneously attack the liver, according to a new animal study from the Icahn School of Medicine at Mount Sinai.

24 Jul 2013

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Inovio Pharmaceuticals, Inc. announced today that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for the treatment of critical limb ischemia and other forms of peripheral arterial disease.

18 Jul 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

Scientists provide insight into emergence of inter-species transmittable viruses

FDA: New drug Tivicay approved to treat HIV-1 infection

Expansion of heroin, opioid medical treatment needed to reduce overdose deaths

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

New findings may lead to first new animal model for hepatitis C virus

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Study: About 50% of fibromyalgia patients have nerve damage

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

World Hepatitis Alliance calls for urgent action to address viral hepatitis

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

Combination treatment can reduce hepatitis C infection in people who inject drugs

Combination of 6 comprehensive measures to prevent spread of hepatitis C

WHO urges governments to act against five hepatitis viruses that cause severe liver infections

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Researchers provide new model for studying drug targets and therapies for AIH

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in